Pociredir is under clinical development by Fulcrum Therapeutics and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase I drugs for Sickle Cell Disease have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pociredir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pociredir overview
Pociredir was under development for the treatment of sickle cell disease. The drug candidate is a differentiated hemoglobin F (HbF) inducer. It is administered though oral route in the form of capsule and acts by targeting gamma-globin and selective EED-targeting PRC2. It is being developed based on FulcrumSeek discovery engine.
It was also under development for the treatment of beta-thalassemia.
Fulcrum Therapeutics overview
Fulcrum Therapeutics is a drug development company. It focuses on the discovery and development of small molecule therapies to unlock gene regulation in diseases. The company’s pipeline products include losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for treating sickle cell disease. The company’s therapeutic areas include neuromuscular, muscular, hematologic, muscle, blood and central nervous system disorders. Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Pociredir’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
